MedTrace Logo

MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.

NCT03611556 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 213

Last updated 2023-10-03

Study results available
· View outcomes & findings →

Summary

The objective of this study is to evaluate the safety, tolerability, and antitumor activity of oleclumab (MEDI9447) in combination with or without durvalumab plus chemotherapy in participants with metastatic pancreatic cancer.

Conditions

  • Carcinoma
  • Metastatic Pancreatic Adenocarcinoma

Interventions

DRUG

Oleclumab

Participants will receive IV infusion of oleclumab as stated in arm description.

DRUG

Durvalumab

Participants will receive IV infusion of durvalumab as stated in arm description.

DRUG

Gemcitabine

Participants will receive IV infusion of gemcitabine as stated in arm description.

DRUG

Nab-paclitaxel

Participants will receive IV infusion of nab-paclitaxel as stated in arm description.

DRUG

Oxaliplatin

Participants will receive IV infusion of oxaliplatin as stated in arm description.

DRUG

Folinic acid

Participants will receive IV infusion of folinic acid as stated in arm description.

DRUG

5-FU

Participants will receive IV infusion of 5-FU as stated in arm description.

Sponsors & Collaborators

  • MedImmune LLC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
101 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-21
Primary Completion
2022-07-22
Completion
2022-07-22
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Norway
  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03611556 on ClinicalTrials.gov